secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2026-07-31T11:23:10+00:00
Accession:  0001193125-26-326784
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics Q2 net loss $17.8M; cash $118M; Phase 3 LEVEL topline data expected Aug 2026
--------------------------------------------------------------------------------

- Net loss of $17.8M for Q2 2026, compared to $10.9M in Q2 2025.
- Cash and cash equivalents of $118.0M as of June 30, 2026; cash runway extended through Q2 2028.
- R&D expenses rose to $12.9M from $6.1M, driven by Phase 3 LEVEL and LEVEL-2 trials.
- Proceeds of $13.4M from warrant exercises in Q2 2026.
- Topline data from Phase 3 LEVEL trial expected in August 2026; LEVEL-2 enrollment targeted by end of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000119312526326784/0001193125-26-326784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000119312526326784/d90330d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-326784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer